Tag Archives: Stem Cells

Stem Cell Treatment Give CMT Patient Second Chance At Life!

“Pat receive a life altering Stem Cell Treatment with the help of World Stem Cells, LLC. Pat went from couch bound to walking 1.5 miles on country dirt road, climbing stairs, gardening and playing piano all thanks to a stem cell treatment.”

Pat is a 69-year-old woman with Charcot-Marie-Tooth disease, or CMT. She had been experiencing the effects of CMT for more than thirty years, and her progressive motor sensory neuropathy had become severe enough to interfere with every aspect of her life. She could no longer play piano, balance well enough to climb up steps or get dressed easily or summon the energy to work for more than a couple of hours before taking a rest break. Pat’s form of CMT is CMT1A, which is the most common form of this autosomal dominant condition. Her symptoms were typical of CMT; patients typically endure progressive muscle wasting and weakness in the legs, and a later loss of hand strength, balance, coordination and fine motor skills.

Pat’s neurological disorder is hereditary, and the official position of the National Institute of Neurological Disorders and Stroke is that CMT has no cure. Decades ago, Pat had gone to a neurologist for electromyography, or EMG. The purpose of the procedure was to evaluate her muscle function, and it involved painful needles and days of muscle soreness after each session. Pat’s neurologist had refused to tell her the results because he said that she would “just give up” if she knew how bad they were. At this point, Pat’s symptoms were so crippling and unbearable that she contacted World Stem Cells, LLC worldstemcells.com to explore stem cell treatment as an option. She knew that the procedures were still being developed and experimental, and that they came with no guarantees. She remained interested in learning more and becoming educated on the options presented. At the time, she was unable to walk without a four-leg quad cane, and air and car travel were exhausting and caused unbearable pain. Pat has a long history of surgeries and was told that further surgeries would not assist her. She decided that she was not interested in any treatment that involved surgery with incisions, which is an aggressive approach and would demand recovery time. Stem cell therapy met her requirements of being minimally uncomfortable, requiring only hours for recovery and having a high level of safety, along with a good potential for changing her health quotient for the better.

Pat arrived in Cancun, Mexico, to the treatment site of World Stem Cells, LLC contract clinics, doctors, and hospitals. The first day, she met with physician Dr. Sylvia M. Abblitt to be evaluated, discuss her course of treatment and learn what to expect. She had been corresponding with Dr. Alan Kadish, the President of World Stem Cells, LLC. worldstemcells.com

Dr. Kadish is an unusual physician as he has training and practiced integrated primary care medicine combining conventional and naturopathic diagnostics and therapeutics for 27 years. He has been recognized as one of the leading quality physicians, in his field. Dr. Kadish is an American Board of Anti-Aging Medicine diplomat and completed numerous training programs in Achieving Clinical Excellence, or ACE, which provided opportunities to improve his practical skills in diagnosing and treating people based on their individual needs, using functional medical testing and treatment. He has been an advanced level practitioner (Autistic Research Institute) for autistic spectral disorder children and adults, since early 2000 and is certified in chelation therapy. As a naturopathic medical physician he lecturers frequently and is a host and guest on radio and internet outlets along with appearing in a number of print media publications. At World Stem Cells , LLC in addition to his management duties, he is a primary investigator engaged in research and designs of stem cell therapeutic protocols.

In Cancun, Pat met with specialists at Advanced Cellular Medicine Clinic. The clinic is headed by Dr. Sylvia Abblitt, who has the exclusive distinction of being among the few physicians who are licensed to perform autologous and allogeneic stem cell transplants in Mexico. Dr. Abblitt is a board-certified hematologist and oncologist. She has 11 years of expertise as a laboratory director and head of the hematology department at the Fernando Quiroz Hospital. She is a member of the American Association of Blood Banks and the International Cellular Medicine Society (ICMS).

The Cancun clinic that Pat visited is a contract clinic of World Stem Cells, LLC. It houses the state-of-the-art Advanced Cellular Engineering Lab. The high-tech lab is suited for providing patients with the most up to date stem cell treatments and for conducting stem cell research to improve future opportunities for health.

After her evaluation and discussion of treatment options, Pat decided to go ahead with the stem cell therapy. The procedure involved a needle puncture to harvest her bone marrow utilizing her own stem cells. Only a local anesthesia was necessary and though she described the procedure as “uncomfortable,” she added that it was“livable.” The procedure took less than half an hour, and she experienced no side effects.

Pat’s improvement was remarkable and rapid. In fact, she did not feel fatigued and overwhelmed with pain, as she had in the past, when she traveled back home from Cancun by airplane and car. Within days, she had regained her ability to play piano. Playing at church concerts had always been a passion of hers, but she had been unable to play before her stem cell treatment because of a lack of coordination. She had much more energy after treatment, and was able to garden, run errands and work, without feeling exhausted. Her sleep was more restful. Her husband and friends noticed that her agility and balance were better. She could climb up and down stairs more easily and walk around the house without clutching the walls. Her speed on the treadmill was increasing gradually and she now walks a mile and a half on country roads.

Pat is extremely grateful to World Stem Cells, LLC for changing her life and giving her hope. For the first time, she has reversed many of the negative changes that she had been experiencing for years due to her CMT and lack of effective treatment. Now, Pat and her husband are experiencing a bright future and thankful that Pat was given this second opportunity, following stem cell therapy.

Working under the guidelines set forth by international cellular medical society (ICMS) World Stem Cells, LLC provides Stem Cell Treatment for Ankylosing Spondylitis, Autism, Cerebral Palsy, Charcot-Marie-Tooth Disease (CMT), Crohn’s Diseases, COPD, Fuch’s disease, Guillain-Barre’ Syndrome, Hashimoto’s Thryroiditis, ITP, Kidney Diseases, Macular Degeneration, Lupus (SLE), Multiple Sclerosis, PAD, Parkinson’s disease, Rheumatoid Arthritis, Scleroderma, Stroke, Ulcerative Colitis at its contract Clinics, GLP laboratory, doctors and hospitals in the beautiful resort area of Cancun. We endeavor to provide the best care possible at a mediate price while providing documentation of all treatments that can be used to provide better future care and scientific data to the medical industry.

Via EPR Network
More Healthcare press releases

Will the Catholic Church & the U.S. Courts Embrace Advanced Cell Technologies “Embryo-Safe” Technique Using Embryonic Stem Cells?

Advanced Cell Technology with laboratory facilities in Marlborough Massachusetts has pioneered a solution to the ethical, moral & legal debate raging in regards to protection of a human embryo. ACT has developed the “single-blastomere” technique. Patent Number 7,893,315 a non-destructive alternative for deriving human embryonic stem cell (hESC) lines.

This achievement in Regenerative medicine is a ground breaking feat for both Catholic and U.S. law.
• The 1995 encyclical The Gospel of Life, of which Pope John Paul II wrote: “Human embryos obtained in vitro are human beings and are subjects with rights; their dignity and right to life must be respected from the first moment of their existence. It is immoral to produce human embryos destined to be exploited as disposable ‘biological material'” (1,5 )
• The Dickey Amendment (also known as the Dickey-Wicker Amendment) is the name of an appropriation bill rider attached to a bill passed by United States Congress in 1995, and signed by former President Bill Clinton, which prohibits the Department of Health and Human Services (HHS) from using appropriated funds for the creation of human embryos for research purposes or for research in which human embryos are destroyed.

The single-blastomere technology uses a one-cell biopsy approach similar to pre-implantation genetic diagnosis (PGD), which is widely used in the in vitro fertilization (IVF) process and does not interfere with the embryo’s developmental potential. The stem cells generated using this approach are healthy, completely normal, and differentiate into all the cell types of the human The safety record for one-cell biopsy as part of PGD now has a 15-year track record, and is carried out routinely as part of IVF processes around the world. ACT’s technique of protecting the human embryo from harm can be expounded to the smallest blood transfusion in the world. As does a human being give millions of blood cells in a pint of blood so does ACT’s “single blastomere” process take but “one cell” from a 2 day old embryo. As the blood removed from a human donor “regenerate” the removed pint of blood so does the human embryo “regenerate” the one cell. Both of these procedures leave the human body & two day old embryo healthy. Both procedures are similar in that they both provide life saving material to those whom need them most to due to disease and other aliments of a medical nature.

Via EPR Network
More Healthcare press releases

Side by side comparison of Advanced Cell Technology & Geron Corporation

Regenerative medicine is a highly complicated and vastly misunderstood science. Investor Stem Cell is dedicated to bringing investors and stakeholders together in thoughtful discussion to educate and publicize the incredible advancements unfolding in the regenerative medicine sector. A quantum leap in health care is upon the world. Will you profit from this emerging sector & help bring cures to millions? Find out now what the street thinks at www.investorstemcell.com.

Side by side comparison of Advanced Cell Technology & Geron Corporation:

Geron Corporation (NASDAQ:GERN), Approved by the FDA to use human embryonic stem cell (hESC) treatments to treat spinal cord injuries. The research Goliath is a well-funded machine employing the top minds in the world working on everything from mid-stage oncology trials to promising (hESC) drugs for spinal cord injuries, heart disease & cancer.

Snap shot of Goliath: Geron Corpoartion-(NASDAQ:GERN)-
• Seven oncology Phase 2 trials currently underway, and has several big Pharma joint venture agreements in oncology animal and human trials
• Five hESC areas of investigation underway. GRNOPC1 is the lead candidate. Geron destroys the human embryo through its (hESC) R&D, of which the company uses the blastocyst embryo formation at day five after fertilization from IVF clinics
• Cash, restricted cash, cash equivalents and marketable securities: $221,274.000.00
• Total operating expenses in 2010: $114,730,000.00
• 175 employees; over 100 hold PhD or MD degrees
• Geron Corporation was founded in 1990 and is based in Menlo Park, California
• Trades on the NASDAQ providing liquidity & large institutional investors
• Corporate financial statements:http://www.geron.com/investors/reports/GeronAnnualReport2010.pdf

Advanced Cell Technology not too long ago was the predominant leader in the field of regenerative medicine. It fell from that distinction in part due to executive management hubris and ultimately the credit crisis in mid-2008. ACT was able to resurrect itself from near bankruptcy in June 2008 and now has the distinction of holding two out of the three FDA approved (hESC) trials. ACT is led by a competent executive management team and employs several of the most predominant regenerative researcher(s) in the world.

Snap shot of David: Advanced Cell Technology-(OTC:ACTC)-
• Retinal Pigment Epithelial Cell Program is their lead program-(HESC) trials for both SMD/AMD are expected to start in week(s) Jules Stein Eye Institute at the University of California, Los Angeles (UCLA ) will conduct the 2 (hESC) trials for Stargardt’s Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD)
• Filed a European Clinical Trial Application for Phase 1/2 study using (hESC) to treat macular degeneration
• Issued a broad patent for hESC-derived RPE cells in China
• Seeking funding & joint venture partner for Myoblast program for the treatment of cardiovascular disease Phase 2 approved by the FDA
• Joint ventured with Korean medical giant CHA to form “Stem Cell & Regenerative Medicine International” (SCRMI). This partnership expected to file an investigational new drug application (IND) with the FDA in Q-4 of this year. CHA biotech is waiting for final approval from the Korea Food and Drug Administration for (hESC) trial for AMD
• Issued patent on its “single-blastomere” technique. Patent Number 7,893,315 broadly covers ACT’s proprietary single-blastomere technology that provides a non-destructive alternative for deriving hESC lines. This “Embryo-Safe” one-cell biopsy approach similar to pre-implantation genetic diagnosis (PGD), which is widely used in the in vitro fertilization (IVF) process and does not interfere with the embryo’s developmental potential
• 22 full-time employees, six hold PhD or MD degrees-Formed in 1994, HQ in Menlo Park, California with laboratory facilities in Marlborough, MA
• Total operating expenses in 2010: $22,044,701
• Cash, restricted cash, cash equivalents and marketable securities: $34,889,409
• Trades on the OTC:BB ACTC is a Sarbanes–Oxley Act SEC reporter
• Corporate financial statements: http://www.sec.gov/Archives/edgar/data/11...

Via EPR Network
More Healthcare press releases

New Website Dedicated To Stem Cell Investors

Investor Stem Cell (http://www.investorstemcell.com) is dedicated to bringing investors and stakeholders together in thoughtful discussion to educate and publicize the incredible medical advancements taking place in the regenerative medicine sector. Scientists are using stem cells both (hESC) and (iPSC) in hopes of easing the suffering of hundreds of millions of people world wide.

Our society is on the verge of a quantum leap moment in time thanks to regenerative medicine.

Regenerative medicine and Stem Cell research:

Utter those words at your next dinner party or casual gathering of friends and family. You will receive a concoction of half-truth’s and out right fallacy responses. Stem Cell research conjures images of futuristic Star–Trek like preservation chambers, human looking ears protruding oddly from the backs of mice, or worse yet an image of a late term fetus. Nothing could be farther from the truth when entering the reality of Regenerative medicine.

Never before has this area of research been more exciting and promising than right now. There is a medical revolution brewing, and like any revolution, there are those who want to suppress this uprising for continued personal and ideological gains. If we were to take all the major advances in the past 500 years of human medical history and multiply its effect by 10 fold it still would not compare to the paradigm shift in health care delivery that the world may witness in this decade using stem cells. Imagine that an $800,000 heart transplant is no longer needed and that instead the same money spent on one patient can now be stretched out to treat 20 patients who are needing a heart transplant. Is this what Regenerative medicine has in the offing? Only time will tell. Our healthcare system could very well be on the verge of a quantum leap moment thanks to regenerative medicine.

The Food and Drug Administration (FDA) authorized 3 trials using human embryonic stem cells (hESC) in late 2010. Validation of hESC research efforts and the culmination of billions spent on research are coming to fruition. FDA validation for the treatments of spinal cord injury and age related macular degeneration is expected in 2011. It may be the shot heard around the world event sometime in late Q-4 2011 for the Regenerative medicine sector.

Via EPR Network
More Healthcare press releases